| Friedrich Wegener and the Nature of Fame | p. 1 |
| Pathogenic Potential of Anti-Neutrophil Cytoplasmic Autoantibodies | p. 7 |
| Neutrophilic Leukocyte Granules: From Structure to Function | p. 17 |
| Pathogenic Aspects of Autoantibodies to Endothelial Cells in Systemic Vasculitis | p. 35 |
| Membrane Surface Proteinase 3 Expression and Intracytoplasmic Immunoglobulin on Neutrophils from Patients with ANCA-Associated Vasculitides | p. 45 |
| A New Approach to the Molecular Characterization of the c-ANCA Antigen in Wegener's Granulomatosis | p. 51 |
| Proteinase 3: Substrate Specificity and Possible Pathogenetic Effect of Wegener's Granulomatosis Autoantibodies (c-ANCA) by Dysregulation of the Enzyme | p. 55 |
| Inhibition of Proteinase 3 Activity by Peptides Derived from Human Epidermis | p. 61 |
| Implications of c-ANCA Testing for the Classification of Wegener's Granulomatosis: Performance of Different Detection Systems | p. 65 |
| ANCA and IgG Subclasses | p. 71 |
| Anti-MPO Antibody (Id) and Autoantibody to Purified Anti-MPO F(Ab)2 (Anti-Id) | p. 77 |
| Cross-Reactivity between Antibodies to Thyroid Microsomal Antigens and Myeloperoxidase | p. 81 |
| Antineutrophil Cytoplasmic Autoantibodies (ANCA) Recognizing a Recombinant Myeloperoxidase Subunit | p. 87 |
| Pooled Human IgG (PHIG) Inhibits the Binding of Anti-Myeloperoxidase Antibodies to Myeloperoxidase | p. 93 |
| Studies to Demonstrate Inhibition of Functional Activity of Neutrophil Lysosomal Enzymes with ANCA | p. 97 |
| Lactoferrin Co-Purifies with Myeloperoxidase and is Recognised by Anti-Neutrophil Cytoplasm Antibodies | p. 101 |
| ANCA Specificities for HL-60 and Neutrophil Constituents | p. 105 |
| In Vitro Interactions of c-ANCA (Antibodies to Proteinase 3) with Human Endothelial Cells | p. 109 |
| Anti-Neutrophil Cytoplasm Antibodies (ANCA) Increase Neutrophil Adhesion to Cultured Human Endothelium | p. 115 |
| Myeloperoxidase Binds to Vascular Endothelial Cells, is Recognized by ANCA and Can Enhance Complement Dependent Cytotoxicity | p. 121 |
| Vascular Permeability Changes Induced by Antibodies to Myeloperoxidase | p. 125 |
| Endothelium Myeloperoxidase, Anti-Myeloperoxidase Interaction in Vasculitis | p. 129 |
| Further Characterization of an Animal Model of Systemic Vasculitis | p. 133 |
| Induction of a Humoral and Cellular (Auto) Immune Response to Human and Rat Myeloperoxidase (MPO) in Brown-Norway (BN), Lewis and Wistar Kyoto (WKY) Rat Strains | p. 139 |
| Disease Associations with Anti-Neutrophil Cytoplasmic Antibodies | p. 145 |
| Classification of Vasculitis | p. 157 |
| Classification of Systemic Vasculitis - A Pathologist's View | p. 165 |
| Polyarteritis Nodosa and Churg-Strauss Syndrome - An Internist's View | p. 173 |
| Vasculitis from the Rheumatologist's Viewpoint | p. 185 |
| A Nephrological View of the Classification of Vasculitis | p. 197 |
| The Nosology of Wegener's Granulomatosis Utilizing the Elk Format Augmented by c-ANCA | p. 209 |
| Vasculitis - The Neurologist's View | p. 217 |
| Treatment of Chronic Idiopathic Systemic Vasculitides | p. 227 |
| Monoclonal Antibody Therapy for Vasculitis | p. 235 |
| Heterogeneity of ANCA Sera Showing Atypical, Peripheral and Classical Cytoplasmic Immunofluorescence Patterns | p. 239 |
| ANCA in Systemic Vasculitides, Collagen Vascular Diseases, Rheumatic Disorders and Inflammatory Bowel Diseases | p. 245 |
| Perinuclear Antineutrophil Cytoplasmic Antibodies (P-ANCA): Clinical Significance and Relation to Antibodies against Myeloid Lysosomal Enzymes | p. 253 |
| Methods of Detection of Anticathepsin G Autoantibodies in Human | p. 257 |
| Anti-Myeloperoxidase Antibodies and Associated Diseases | p. 263 |
| Autoantibodies Directed against Lysozyme: A New Target Antigen for Anti-Neutrophil Cytoplasmic Antibodies (ANCA) | p. 267 |
| Clinical Significance of ANCA in 98 Patients | p. 273 |
| Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA): Antigenic Specificities and Clinical Associations | p. 281 |
| Significance of Autoantibodies to Purified Proteinase 3 in Systemic Vasculitis | p. 287 |
| Characterization Anti-Myeloperoxidase Antibodies in Vasculitis | p. 291 |
| Low Predictive Value of c-ANCA and Anti-[alpha]-Granule Antibody for Vasculitis in Hong Kong | p. 295 |
| Detection and Clinical Associations of Autoantibodies to Myeloid Granular Proteins | p. 299 |
| Relationship between Disease Activity and ANCA Level by ELISA in the Long-Term Management of Vasculitis | p. 303 |
| ANCA in Ocular Inflammatory Disorders | p. 305 |
| Head and Neck Involvement in Wegener's Granulomatosis (WG) | p. 309 |
| Orbital Involvement in Wegener's Granulomatosis | p. 315 |
| MRI of the Head in Wegener's Granulomatosis | p. 319 |
| The Clinical, Serologic, and Immunopathologic Heterogeneity of Cutaneous Leukocytoclastic Angiitis | p. 323 |
| No ANCA in Thromboangiitis Obliterans (Burger's Disease) | p. 327 |
| Alpha-1-Proteinase Inhibitor and Pulmonary Haemorrhage in Systemic Vasculitis | p. 331 |
| Alpha-1-Antitrypsin, CRP and Interleukin-6 in ANCA-Positive Vasculitis | p. 337 |
| Pro- and Anti-Inflammatory Cytokines in Primary Systemic Vasculitis | p. 341 |
| Problems of Classification in Necrotizing Vasculitis | p. 345 |
| Anti-Neutrophil Cytoplasm Antibodies in HIV Infections | p. 349 |
| Anti-Neutrophil Cytoplasmic Antibodies (ANCA) and Infection | p. 353 |
| Anti-Lactoferrin Antibodies in Patients with Rheumatoid Arthritis with Vasculitis | p. 357 |
| Anti-Neutrophil Cytoplasmic Antibodies in Giant Cell Arteritis and Polymyalgia Rheumatica | p. 363 |
| Antibodies to Neutrophil Cytoplasmic Antigens in Rheumatoid Arthritis | p. 367 |
| Incidence and Specificity of p-ANCA in Rheumatic Diseases | p. 371 |
| Anti-Granulocyte Perinuclear Antibodies but not Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Rheumatoid Arthritis | p. 375 |
| Anti-Neutrophil Cytoplasmic Antibodies in Patients with Systemic Lupus Erythematosus | p. 381 |
| ANCA with Specificity for Lactoferrin in Systemic Lupus Erythematosus (SLE) | p. 385 |
| Serum Markers of T-Cell Activation in Relapses of Wegener's Granulomatosis | p. 389 |
| Presence of Anticardiolipin Antibodies Discriminates between Wegener's Granulomatosis and Microscopic Polyarteritis | p. 393 |
| Increased Expression of CD25 and Adhesion Molecules on Peripheral Blood Lymphocytes of Patients with Wegener's Granulomatosis (WG) and ANCA Positive Vasculitides | p. 397 |
| Wegener's Granulomatosis with Severe Peripheral and Central Neuropathy - Case Report | p. 405 |
| Limited Prognostic Value of Changes in Antineutrophil Cytoplasmic Antibody Titers in Patients with Wegener's Granulomatosis | p. 411 |
| Wegener's Granulomatosis and Henoch-Schonlein Purpura in a Family with Hereditary C4 Deficiency | p. 415 |
| Little Evidence for Anti-Endothelial-Cell Antibodies in Microscopic Polyarteritis and Wegener's Granulomatosis | p. 419 |
| Prevalence of ANCAs in Patients on Maintenance Haemodialysis | p. 423 |
| Rhabdomyolysis in Vasculitis | p. 427 |
| Rapidly Progressive Glomerulonephritis (RPGN): Is There Still an "Idiopathic" Subgroup? | p. 431 |
| Association between Silica Exposure and Necrotizing Crescentic Glomerulonephritis with p-ANCA and anti-MPO Antibodies: A Hospital-Based Case-Control Study | p. 435 |
| ANCA and Anti-GBM Antibodies in RPGN | p. 441 |
| p-ANCA with Myeloperoxidase Antibodies and c-ANCA with Proteinase 3 Antibodies Define a Different Vasculitis Entity in Patients with Renal Involvement | p. 445 |
| Antineutrophil-Cytoplasmic-Autoantibodies in Poststreptococcal Nephritis | p. 449 |
| Identification of Apparent Dual ANCA Specificities in a Subset of Patients with Systemic Vasculitis and Crescentic Glomerulonephritis | p. 455 |
| c-ANCA and p-ANCA Positive Vasculitis with Crescentic Glomerulonephritis: The Same Clinical Feature but Different Immunological Pathways? | p. 461 |
| Clinical Manifestations in Patients on Chronic dialysis with High Titres of ANCA | p. 465 |
| Pooled Intravenous Immunoglobulin in the Management of Systemic Vasculitis | p. 469 |
| Cyclosporin A Therapy for Wegener's Granulomatosis | p. 473 |
| Necrotizing Vasculitis - Relapse Despite Cytotoxic Therapy | p. 477 |
| Effectiveness of Cyclophosphamide Pulse Treatment in Wegener's Granulomatosis | p. 483 |
| Treatment of Wegener's Granulomatosis with Intravenous Immunoglobin | p. 487 |
| Treatment of Wegener's Granulomatosis | p. 491 |
| Treatment Modalities and ANCA in Takayasu's Arteritis | p. 497 |
| Late Recurrence of Systemic Vasculitis after Kidney Transplantation Involving the Kidney Allograft | p. 503 |
| P-ANCA of Undefined Specificity in Ulcerative Colitis: Correlation to Disease Activity and Therapy | p. 507 |
| Anti-Neutrophil cytoplasmic Auto-Antibodies (ANCA) in Patients with Ulcerative Colitis (UC): Influence of Disease Activity and Familial Study | p. 515 |
| Antineutrophil Antibodies in Inflammatory Bowel Disease Recognize Different Antigens | p. 519 |
| Anti-Neutrophil Cytoplasmic Auto-Antibodies in Sera from Patients with Ulcerative Colitis after Proctocolectomy with Ileo-Anal Anastomosis | p. 523 |
| p-ANCA as a Diagnostic Marker in Ulcerative Colitis | p. 527 |
| Lactoferrin, Anti-Lactoferrin Antibodies and Inflammatory Disease | p. 533 |
| Detection of Antineutrophil Cytoplasmic Antibodies (ANCA) and their Association with Other Autoantibodies in Patients with Hepatobiliary Disorders | p. 539 |
| Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Autoimmune Liver Disease | p. 545 |
| Index | p. 551 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
